Vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate: The role of pre-treatment bone turnover

被引：0
|
作者：
Seibel, MJ
Barton, I
Grauer, A
机构：
[1] Univ Sydney, Sydney, NSW 2006, Australia
[2] Procter & Gamble Pharmaceut, Geneva, Switzerland
来源：
OSTEOPOROSIS INTERNATIONAL | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [21] BONE MARKER CHANGES IN RISEDRONATE-TREATED POSTMENOPAUSAL WOMEN
    SMITH, J
    SHOUKRI, K
    TRAHIOTIS, M
    FALL, P
    WOODIEL, F
    RAISZ, L
    BEKKER, P
    LOWRY, C
    SACCOGIBSON, N
    JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S351 - S351
  • [22] Risedronate rapidly reduces vertebral fracture risk in postmenopausal women with established osteoporosis
    Roux, C
    Miller, P
    Gennari, C
    Keller, M
    Sorensen, O
    Ritter-Hrncirik, C
    Barton, I
    Watts, N
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S287 - S287
  • [23] Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures
    Hadji, P.
    Zanchetta, J. R.
    Russo, L. A.
    Recknor, C. P.
    Saag, K. G.
    McKiernan, F. E.
    Silverman, S. L.
    Alam, J.
    Burge, R. T.
    Krege, J. H.
    Lakshmanan, M. L.
    Masica, D. N.
    Mitlak, B. H.
    Stock, J. L.
    BONE, 2011, 48 : S82 - S83
  • [24] Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate
    Gamsjaeger, Sonja
    Buchinger, Birgit
    Zoehrer, Ruth
    Phipps, Roger
    Klaushofer, Klaus
    Paschalis, Eleftherios P.
    BONE, 2011, 49 (06) : 1160 - 1165
  • [25] EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture
    Triantafyllopoulos, Ioannis K.
    Lambropoulou-Adamidou, Kalliopi
    Nacopoulos, Cleopatra C.
    Papaioannou, Nikolaos A.
    Ceausu, Iuliana
    Depypere, Herman
    Erel, C. Tamer
    Perez-Lopez, Faustino R.
    Schenck-Gustafsson, Karin
    van der Schouw, Yvonne T.
    Simoncini, Tommaso
    Tremollieres, Florence
    Rees, Margaret
    Lambrinoudaki, Irene
    MATURITAS, 2014, 78 (02) : 131 - 137
  • [26] Medico-economic evaluation of vertebral fracture in osteoporotic postmenopausal women
    Reygrobellet, C
    Maurel, F
    Jamonneau, I
    Liu-Leage, S
    Alfonsi, A
    Le Pen, C
    Roux, C
    VALUE IN HEALTH, 2004, 7 (06) : 723 - 723
  • [27] Pre-treatment bone turnover and the anti-fracture efficacy of raloxifene.
    Bauer, D. C.
    Blackwell, T.
    Delmas, P. D.
    Cummings, S. R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S185 - S185
  • [28] EFFECTIVENESS OF DIFFERENT MODALITIES FOR OSTEOPOROTIC POSTMENOPAUSAL WOMEN WITHOUT VERTEBRAL FRACTURE
    Patru, S.
    Bighea, A.
    Popescu, R.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 47 - 47
  • [29] The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
    P. Hadji
    J. R. Zanchetta
    L. Russo
    C. P. Recknor
    K. G. Saag
    F. E. McKiernan
    S. L. Silverman
    J. Alam
    R. T. Burge
    J. H. Krege
    M. C. Lakshmanan
    D. N. Masica
    B. H. Mitlak
    J. L. Stock
    Osteoporosis International, 2012, 23 : 2141 - 2150
  • [30] INCIDENCE OF OSTEOPOROTIC VERTEBRAL FRACTURES WITH ELDERLY POSTMENOPAUSAL WOMEN: OUR EXPERIENCE
    Karadzic, Mirjana S.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S240 - S240
12345